Tesamorelin
GHRH analogue that supports GH release and promotes visceral fat reduction.
Tesamorelin
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with an N-terminal modification that enhances stability. It is particularly noted for its selective influence on visceral adipose tissue — the metabolically active fat stored around the abdomen.
How It Works
Tesamorelin binds to GHRH receptors on pituitary cells, stimulating pulsatile GH secretion and subsequent IGF-1 production. The elevated GH/IGF-1 axis drives lipolysis preferentially in visceral fat depots, supporting a leaner midsection and improved body composition.
Key Benefits
• Visceral Fat Reduction:: Selectively targets visceral adipose tissue for fat mobilization
• GH Axis Support:: Stimulates natural, pulsatile GH release through GHRH receptor activation
• Body Composition:: Supports lean mass while reducing central adiposity
• Enhanced Stability:: N-terminal modification provides resistance to enzymatic degradation
Structural Properties
Tesamorelin has a molecular weight of 5135.9 Da (CAS: 218949-48-5). The trans-3-hexenoic acid N-terminal modification extends functional half-life while maintaining full receptor binding activity.
Quality and Purity
Supplied as a lyophilized powder with purity ≥98.0% verified by HPLC and mass spectrometry. Each vial contains 2 mg.
Storage
Store at 2–8°C. Stable for 18 months unopened. Protect from light and moisture.
Product Details
Storage & Handling
Store at 2-8°C. Stable for 18 months unopened.
Related Products
AOD-9604
Modified GH fragment that targets fat metabolism and supports body composition.
HGH Fragment 176-191
C-terminal GH fragment that selectively promotes fat burning without affecting growth.